Genetics of multiple myeloma: another heterogeneity level?

Our knowledge of myeloma genetics remained limited and lagged behind many other hematologic malignancies because of the inherent difficulties in generating metaphases within the malignant plasma cell clone. With the development of molecular techniques (microarrays and next-generation sequencing), our understanding has been highly improved in the past 5 years. These studies have not only confirmed the prevalence of wide heterogeneity in myeloma at the molecular level, but has also provided a much clearer picture of the disease pathogenesis and progression. Whether these data will enable improvements in the therapeutic approach is still a matter of debate. The next improvement will come from detailed analyses of these molecular features to try to move from a treatment fitted to every patient to individualized therapies, taking into account the complexity of the chromosomal changes, the mutation spectrum, and subclonality evolution.

[1]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[2]  P. Moreau,et al.  The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma , 2013, Clinical Cancer Research.

[3]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[4]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[5]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[6]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.

[7]  R. Howard,et al.  A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.

[8]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[9]  Yi Li,et al.  Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma , 2014, Leukemia.

[10]  B. Grosbois,et al.  Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials , 2007, Leukemia.

[11]  F. Speleman,et al.  Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. , 2013, Blood.

[12]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[13]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[14]  R. Fonseca,et al.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. , 2003, Blood.

[15]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[16]  V. Carlton,et al.  Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients , 2013 .

[17]  N. Munshi,et al.  Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. , 2015, Blood.

[18]  J. Mary,et al.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.

[19]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[20]  D. Reece,et al.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant , 2004, British journal of haematology.

[21]  Giovanni Parmigiani,et al.  Differential and limited expression of mutant alleles in multiple myeloma. , 2014, Blood.

[22]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[23]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[24]  T. Soussi,et al.  Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma , 2010, Haematologica.

[25]  G. Morgan,et al.  Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. , 2013, Blood.

[26]  F. Zhan,et al.  A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. , 2003, Blood.

[27]  Cheng Li,et al.  Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.

[28]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[29]  I. Hanamura,et al.  Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations , 2001, Japanese journal of cancer research : Gann.

[30]  L. Staudt,et al.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. , 2004, Cancer cell.

[31]  J. Cigudosa,et al.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations , 1997, Genes, chromosomes & cancer.

[32]  H. Goldschmidt,et al.  Targeting the BRAF V600E mutation in multiple myeloma. , 2013, Cancer discovery.

[33]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[35]  B. Pégourié,et al.  Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Sonneveld,et al.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. , 2010, Blood.

[37]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[38]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[40]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[41]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[42]  L. Chin,et al.  High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. , 2006, Cancer cell.

[43]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[44]  A. Tefferi,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[45]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[46]  B. Pégourié,et al.  Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients , 2014, Leukemia.

[47]  L. Escoda,et al.  Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis , 2007, Leukemia.

[48]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Keats,et al.  Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma , 2014, Leukemia.

[50]  L. Staudt,et al.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. , 2011, Blood.

[51]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[52]  M. Shipp,et al.  Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. , 2005, Blood.

[53]  N. Munshi,et al.  Minor clone provides a reservoir for relapse in multiple myeloma , 2013, Leukemia.

[54]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[55]  E. Schröck,et al.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.

[56]  P. L. Bergsagel,et al.  Early genetic events provide the basis for a clinical classification of multiple myeloma. , 2005, Hematology. American Society of Hematology. Education Program.

[57]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[59]  G. Ahmann,et al.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.

[60]  N. Munshi,et al.  Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. , 2009, Blood.

[61]  D. Gerhard,et al.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. , 1996, Blood.

[62]  G. Ahmann,et al.  Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma , 2006, Leukemia.